THE Competition Commission last week announced that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, were under investigation for allegedly engaging in exclusionary practices and excessive pricing of bedaquiline.
The drug is sold under the brand name Sirturo.
The commission said its investigation was based